Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Medigus Ltd ADR is a medical devices business based in the US. Medigus Ltd ADR shares (MDGS) are listed on the NASDAQ and all prices are listed in US Dollars. Medigus Ltd ADR employs 26 staff and has a trailing 12-month revenue of around $42.7 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $5.03 |
|---|---|
| 52-week range | $3.95 - $16.99 |
| 50-day moving average | $5.78 |
| 200-day moving average | $9.06 |
| Wall St. target price | N/A |
| PE ratio | 23.8571 |
| Dividend yield | $0 (16.83%) |
| Earnings per share (TTM) | $0.21 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.032 from 2023-01-27
| 1 week (2023-01-23) | 0.64% |
|---|---|
| 1 month (2022-12-30) | 7.75% |
| 3 months (2022-10-28) | 986.83% |
| 6 months (2022-07-29) | 778.18% |
| 1 year (2022-01-28) | 459.11% |
|---|---|
| 2 years (2021-01-29) | 79.71% |
| 3 years (2020-01-30) | 190.87% |
| 5 years (2018-01-30) | 231.05% |
Valuing Medigus Ltd ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medigus Ltd ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medigus Ltd ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Medigus Ltd ADR shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $42.7 million |
|---|---|
| Gross profit TTM | $4.8 million |
| Return on assets TTM | -5.23% |
| Return on equity TTM | -16.12% |
| Profit margin | -15.42% |
| Book value | $27.54 |
| Market capitalisation | $8.2 million |
TTM: trailing 12 months
We're not expecting Medigus Ltd ADR to pay a dividend over the next 12 months.
Medigus Ltd ADR's shares were split on a 1:15 basis on 13 November 2022. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Medigus Ltd ADR shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Medigus Ltd ADR shares which in turn could have impacted Medigus Ltd ADR's share price.
Over the last 12 months, Medigus Ltd ADR's shares have ranged in value from as little as $3.9466 up to $16.9886. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medigus Ltd ADR's is 1.4196. This would suggest that Medigus Ltd ADR's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Medigus Ltd. , a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
